GeneProt and Bruker Daltonics Plan Large-Scale Deployment of MALDI- TOF/TOF Mass Spectrometers for High-Throughput Proteomics

Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, incl...

Full description

Saved in:
Bibliographic Details
Published inBusiness Wire p. 1
Main Author Business/Technology Editors & Health/Medical Writers BioWire 2K
Format Newsletter
LanguageEnglish
Published New York Business Wire 07.11.2001
Subjects
Automation
Bioinformatics
Chief executive officers
Ions
Mass spectrometry
Pharmaceutical industry
Product development
Proteins
Proteomics
Scientific imaging
Software
Online AccessGet full text

Cover

More Information
Summary:Bruker Daltonics is a leading provider of innovative life science tools based on mass spectrometry. Its substantial investment in research and development allows it to design, manufacture and market a broad array of products intended to meet the rapidly growing needs of a diverse customer base, including pharmaceutical companies, biotechnology companies, proteomics companies, molecular diagnostics companies, academic institutions and government agencies. Bruker Daltonics has diverse technology platforms that integrate automated sample preparation and clean-up, advanced front-end AnchorChip(TM) MALDI targets and API source technology with cutting-edge proprietary MALDI-TOF, MALDI-TOF/TOF, ESI-TOF, ESI-Q-q-TOF, ion trap and FTMS mass analyzers, as well as analysis and bioinformatics software. Bruker Daltonics is also a worldwide leader in supplying mass spectrometry-based systems for substance detection and pathogen identification in security, defense and anti-terrorism applications. Further information is available at: www.bdal.com. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements of Bruker Daltonics as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.